Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus IST vs placebo plus IST in treatment-naïve severe aplastic anemia
CTR20254900Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of romiplostim in aplastic anemia, sponsored by Qilu Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on CTR20254900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254900.